Benzathine analogs

Patent metadata

Field	Value
Publication number	US-11857550-B2
Application number	US-202016953201-A
Country	US
Kind code	B2
Filing date	Nov 19, 2020
Priority date	Jun 8, 2012
Publication date	Jan 2, 2024
Grant date	Jan 2, 2024

Abstract

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

wherein X is a divalent linking moiety; and
R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

First claim

What is claimed is:

1. A method for inhibiting pro-inflammatory cytokine release in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

2. A method for treating an inflammatory disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof;
wherein the inflammatory disorder is at least one of asthma, chronic obstructive lung disease, pulmonary fibrosis, pneumonitis, pneumonia, cystic fibrosis, psoriasis, arthritis, rheumatoid arthritis, rhinitis, pharyngitis, cystitis, prostatitis, dermatitis, allergy, nephritis, conjunctivitis, encephalitis, meningitis, opthalmitis, uveitis, pleuritis, pericarditis, myocarditis, atherosclerosis, human immunodeficiency virus inflammation, diabetes, osteoarthritis, psoriatic arthritis, inflammatory bowel disease, colitis, sepsis, vasculitis, bursitis, connective tissue disease, autoimmune disease, viral or influenza-induced inflammation, and edema.

3. The method of claim 2 , wherein the inflammatory disorder is sepsis.

4. The method of claim 2 , wherein the inflammatory disorder is pneumonia.

5. The method of claim 2 , wherein the inflammatory disorder is induced by infection with at least one of Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza , and Escherichia coli.

6. The method of claim 2 , wherein the inflammatory disorder is chronic obstructive lung disease.

7. The method of claim 2 , wherein the inflammatory disorder is inflammatory bowel disease.

8. The method of claim 2 , wherein the inflammatory bowel disease is Crohn's disease.

9. The method of claim 2 , wherein the inflammatory disorder is colitis.

10. A method for treating an FBXO3-mediated disorder or injury in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound

or a pharmaceutically acceptable salt thereof;
wherein the FBXO3-mediated disorder or injury is at least one selected from malaria, toxic lung exposure, cancer, Alzheimer's, and a burn-related injury;
wherein the cancer is at least one selected from leukemia, lymphoma, bronchogenic carcinoma, adenocarcinoma of the breast, colon, ovary, thyroid, pancreas, stomach, or prostate, squamous cell cancer, small cell cancer, melanoma, sarcoma, and metastatic cancer.

11. A method for inhibiting FBXO3-induced ubiquitination and degradation of FBXL2 in a subject in need thereof, the method comprising contacting FBXO3-containing tissue or cells with the compound:

or a pharmaceutically acceptable salt thereof.

12. A method for inhibiting bacterial growth in a subject in need thereof or on a surface of an object, the method comprising administering to the subject or the surface of the object an effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

13. A method for diminishing supraphysiological levels of at least one of TNFα, IL-β, and IL-6 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Us Gov Veterans Affairs

Inventors

• Chen Beibei
• Mallampalli Rama K

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/341

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• A61K31/381

  having five-membered rings · CPC title